Senti Biosciences (SNTI) Total Current Liabilities (2021 - 2025)

Senti Biosciences has reported Total Current Liabilities for 5 years, with the latest figure at $14.0 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities rose 6.3% year-over-year to $14.0 million; the trailing twelve-month figure through Dec 2025 stood at $14.0 million (up 6.3% YoY), and the FY2025 full-year result was $14.0 million, up 6.3% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $14.0 million, up from $12.0 million in the prior quarter.
• The five-year high for Total Current Liabilities was $18.1 million in Q4 2022, with the low at $61025.0 in Q2 2021.
• Average Total Current Liabilities over 5 years is $10.7 million, with a median of $10.7 million recorded in 2025.
• Year-over-year, Total Current Liabilities soared 29065.1% in 2022 and slumped 41.42% in 2023.
• Tracing SNTI's Total Current Liabilities over 5 years: stood at $14.5 million in 2021, then rose by 24.14% to $18.1 million in 2022, then retreated by 29.81% to $12.7 million in 2023, then climbed by 3.74% to $13.1 million in 2024, then grew by 6.3% to $14.0 million in 2025.
• The last three Total Current Liabilities figures came in at $14.0 million (Q4 2025), $12.0 million (Q3 2025), and $10.0 million (Q2 2025), per Business Quant data.

Peer Comparison